Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Pharmaceutical intervention improves drug knowledge, reduces anxiety in patients with cancer

09 Sep 2017

A recently launched pharmacist outpatient service has been shown to deepen understanding of the medications’ side effects and ease anxiety levels in patients undergoing monotherapy with oral anticancer agents, according to a Japan study.

Researchers obtained data on prescription recommendations from the drug management guidance records of 154 patients who consulted the pharmacist outpatient service between July 2013 and September 2015 to assess the role and usefulness of the said intervention. They also calculated the rates of prescription recommendation adherence.

A self-reported questionnaire was administered between April and August 2015 to 47 patients undergoing oral monotherapy with anticancer agents who were visiting the pharmacist outpatient service at the Ogaki Municipal Hospital in Japan.

A total of 235 cases received prescription recommendations, with a 94.9 percent total adherence rate (223/235 cases). Most prescription recommendations on supportive care were those for moisturizing agents (20.9 percent), analgesics (20.9 percent), steroid ointments (12.7 percent) and antihypertensive agents (10.8 percent).

There were significant changes seen for survey items 3 (knowing the side effects of the medication; p=0.0049), 8 (worrying about the side effects; p<0.0001) and 12 (interest in prescribed medicine; p=0.0164) when continued pharmaceutical intervention was provided.

The involvement of pharmacists is warranted for outpatients when quick feedback to physicians must be provided (eg, monitoring therapy with the oral anticoagulant warfarin or providing therapeutic support for patients undergoing cancer chemotherapy), according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).